Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported paired option exercises and stock sales in Class A Common Stock. He exercised options covering 1,040 shares at $1.01 per share and sold 1,040 shares at $16.00 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse.
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and share sale in Class A Common Stock. He exercised stock options for 2,500 shares at $1.01 per share and sold 2,500 shares at $16.00 per share on July 8, 2026. These trades were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, he holds 17,217 shares directly and 279,430 stock options expiring on February 24, 2030.
CTNM: Proposed sale of 2,500 common shares by exercise of stock options for cash. The filing shows 2,500 Common shares to be sold on 07/08/2026 via an Exercise of Stock Options with cash indicated. The notice also records prior 10b5-1 sales by Carmine Stengone of 10,000 shares on 06/30/2026 for $160,080.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported mixed equity transactions in Class A Common Stock. On June 30 and July 1, he sold a total of 37,179 shares in open-market trades at weighted average prices around $15.67–$16.24 per share under a pre-arranged Rule 10b5-1 trading plan. He also exercised stock options for 33,009 shares at an exercise price of $1.01 per share, converting options into common stock. After these transactions, he holds 135,202 shares directly and 10,110 shares indirectly through his spouse, along with 34,297 fully vested stock options that remain exercisable.
Contineum Therapeutics, Inc. executive Tim Watkins, CMO & Head of Development, reported an exercise-and-sell transaction in Class A Common Stock. On June 30, 2026, he exercised stock options to acquire 10,833 shares at an exercise price of $4.50 per share and sold 10,833 shares in open-market trades at a weighted average price of $16.0242 per share, with individual sale prices ranging from $16.00 to $16.15. The sale was carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he directly holds 19,794 shares of Class A Common Stock, which includes 8,961 shares acquired through the company’s Employee Stock Purchase Plan, and retains 238,334 stock options with a $4.50 exercise price expiring on April 27, 2035, subject to continued vesting.
Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and on the same day sold 10,000 shares in an open-market transaction. The sale used a weighted average price of $16.008 per share, with individual trades between $16.00 and $16.12.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, Stengone directly holds 17,217 Class A shares, including 5,605 acquired through the company’s Employee Stock Purchase Plan, and retains stock options covering 118,417 shares at $1.26 and 281,930 shares at $1.01 exercise prices.
CTNM reported Form 144 sales by an insider on 06/30/2026 and earlier dates. The filing lists multiple 10b5-1 plan sales: 28,826 shares on 06/30/2026 for $462,288.02; 4,170 shares on 06/01/2026 for $54,862.19; 4,170 shares on 05/01/2026 for $54,707.48; and 4,170 shares on 04/06/2026 for $56,013.94. The filing also records an exercise of stock options of 5,350 shares on 07/01/2026 and 4,170 restricted stock units dated 05/09/2017.
CTNM submitted a notice to sell 28,826 shares of Common Stock. The filing lists the method as an Exercise of Stock Options with proceeds shown as $432,390.00 and identifies the broker as Morgan Stanley Smith Barney LLC. Shares outstanding were 32,723,877 as of 06/30/2026. The filing also discloses recent 10b5-1 sales by Daniel Lorrain of 4,170 shares on 04/06/2026, 05/01/2026, and 06/01/2026 with aggregate proceeds shown for each sale.